SR9011
Chemical compound
From Wikipedia, the free encyclopedia
SR9011 is a research drug that was developed by Professor Thomas Burris of Scripps as an agonist of Rev-ErbAα with a half-maximum inhibitory concentration (IC50) = 790 nM for Rev-Erbα and IC50 = 560 nM for Rev-ErbAβ.[1] It has been used in the study of the regulation of the circadian rhythm and its links to immune system function, inflammation and cancer.[2][3][4][5][6][7]
| Identifiers | |
|---|---|
| |
| CAS Number | |
| PubChem CID | |
| ChemSpider | |
| UNII | |
| ChEMBL | |
| CompTox Dashboard (EPA) | |
| Chemical and physical data | |
| Formula | C23H31ClN4O3S |
| Molar mass | 479.04 g·mol−1 |
| 3D model (JSmol) | |
| |
| |